Post-chemotherapy robot-assisted retroperitoneal lymph node dissection for metastatic germ cell tumors: safety and perioperative outcomes.

Journal: World journal of urology
PMID:

Abstract

PURPOSE: To evaluate the feasibility, safety, and early oncologic outcomes after post-chemotherapy robot-assisted retroperitoneal lymph node dissection (PC-RARPLND) for metastatic germ cell tumors (mGCT).

Authors

  • Nicolas Branger
    Department of Urology, Institut Paoli-Calmettes, Marseille, France.
  • Franck Bladou
    Department of Urology; Jewish General Hospital, McGill University, Montreal, QC, Canada.
  • Grégory Verhoest
    Department of Urology, Rennes University Hospital, 2, rue Henri Le Guilloux, 35033, Rennes Cedex, France.
  • Sophie Knipper
    Martini-Klinik Prostate Cancer Center, Hamburg, Germany.
  • Grégoire Robert
    Department of Urology, Bordeaux University Hospital, Bordeaux, France.
  • Jean-Christophe Bernhard
    Department of Urology, University of Bordeaux, Bordeaux, France.
  • Jean-Baptiste Beauval
    Department of Urology, University of Toulouse, Toulouse, France.
  • Abderrahmane Khaddad
    Department of Urology, CHU Bordeaux, Bordeaux, France.
  • Anne Mauger De Varennes
    Department of Urology, CHU Rennes, Rennes, France.
  • Aude Fléchon
    Department of Oncology, Centre Léon Bérard, Lyon, France.
  • Jochen Walz
    Institut Paoli-Calmettes, Service de chirurgie urologique, Marseille, France.
  • Anne-Sophie Bageot
    Department of Urology, CHU Toulouse, Toulouse, France.
  • Nicolas Doumerc
    Department of Urology, University of Toulouse, Toulouse, France.
  • Morgan Rouprêt
    Centre de Recherche sur les Pathologies Prostatiques, Paris, France; GRC No. 5 Predictive Onco-Urology, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, France.
  • Thibault Murez
    Department of Urology, CHU Montpellier, Montpellier, France.